Summary & Overview
HCPCS Level II J3130: Injection, Testosterone Enanthate, Up to 200 mg
HCPCS Level II code J3130 denotes an injection of testosterone enanthate, up to 200 mg. This code matters nationally because injectable testosterone preparations are commonly used for hormone replacement and certain endocrine therapies, and accurate coding affects clinical billing, coverage determinations, and data capture for utilization. Payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what the code represents, typical sites of service, and the clinical context for use. The publication outlines payer coverage considerations and billing benchmarks where available, highlights relevant coding relationships, and summarizes policy or reimbursement updates that affect injectable testosterone administration. The piece also identifies common operational issues in billing this drug formulation and what to expect in claims processing and documentation. Data not available in the input will be noted where applicable.
Billing Code Overview
HCPCS Level II code J3130 represents an injection of testosterone enanthate, up to 200 mg. This code is used to bill for the drug administration itself as described by the product and dose.
Service Type: Medication administration (injectable formulation)
Typical Site of Service: Outpatient clinic, physician office, or other ambulatory setting where injectable testosterone is administered
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult male with documented hypogonadism requiring intramuscular testosterone replacement. The patient presents to an outpatient infusion clinic, primary care office, or urology/endocrinology clinic for administration of J3130 (injection, testosterone enanthate, up to 200 mg). The clinical workflow includes: a pre-visit medication reconciliation and brief assessment of symptoms and recent labs (total testosterone level, hematocrit), verification of dose and formulation, consent for intramuscular injection, preparation of medication by a licensed clinician or qualified staff, administration via deep intramuscular injection (typically into the gluteal or deltoid muscle), observation for immediate adverse reaction, documentation of lot number, dose, route, site, and patient response, and scheduling of follow-up doses and periodic monitoring (testosterone level, PSA if age-appropriate, hematocrit). Typical sites of service are outpatient clinic, physician office, or ambulatory infusion center. Common clinical scenarios include primary or secondary hypogonadism, gender-affirming hormone therapy for transgender male patients, and delayed puberty management under specialist care.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 | Significant, separately identifiable evaluation and management service by the same physician on the same day of the procedure | Use when an E/M visit is performed on the same day as the injection and meets documentation for a separate medically necessary E/M |